Institute for Genomic Medicine Project Aims to Find Candidate Treatments for AHC
Taken from the press release HERE
Rolesville, NC, December 7, 2015 – Cure AHC, Inc. has awarded a grant of $75,000 to Columbia University Institute for Genomic Medicine (IGM) for the Multiple Electrode Array (MEA) Compound Screening Project with Optogenetics for Alternating Hemiplegia of Childhood (AHC) Mouse Model. The Project will enable the team to rapidly screen a wide array of compounds to test the potential for efficacy, and at the same time gain deeper understanding of the molecular and cellular functions and malfunctions at work in the disease. It will also help provide rich data on efficacy when and if candidate compounds are identified, or point the way for development of new compounds. It will also help more consistently produce the conditions of the episodic nature of AHC, for more accurate and consistent research results.
“We are hopeful that this project will fill in some key gaps in knowledge about AHC and propel us forward with candidates for treatment” said Erin Heinzen, PhD, Deputy Director of the Institute for Genomic Medicine (and Project Leader) and Assistant Professor of Pathology and Cell Biology at Columbia University Medical Center.
“Cure AHC recognizes the strategic nature of this important work at the IGM, and applauds this collaborative effort that augments our previous research investments” said Cure AHC Co-Founder and President Jeff Wuchich. Cure AHC has also launched the 2015 End of Year Global Challenge Grant Campaign, with plans to fund several other collaborative and complementary research projects in 2016.